OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- final report now available
The final report is now available for the Relative Effectiveness Assessment OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)”. The aim of this multi-technology HTA was to assess 21 minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), either comparing minimally invasive treatments to each other or […]
PTJA13 – Publication of Project Plan.
PTJA13 – Satralizumab is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive – the project plan is now available. Due to unexpected changes to the timelines of […]
EMA-EUnetHTA Bilateral Meeting held today.
The concluding EMA-EUnetHTA Bilateral Meeting under Joint Action 3 was held online today, marking a fitting conclusion to another stage of regular ongoing collaboration that stretches back through all three Joint Actions to the first bilateral meetings in 2010. Participants reviewed the joint achievements under the EMA/EUnetHTA workplan 2017-2021, showcasing the value of their collective […]
EUnetHTA-EFPIA Meeting Summary Now Available
We are pleased to publish the summary from the EUnetHTA-EFPIA Technical Meeting, held online on 1st December, 2020. Please follow the link to download. EUnetHTA-EFPIA Technical Meeting Summary – Dec 2020
EMA-EUnetHTA Bilateral – December 2020 minutes now available
We are please to publish the minutes from the EMA-EUnetHTA Bilateral meeting, held 16 December 2020 online. Thanks to all attendees, and the continuing joint work undertaken by this collaboration. Access here: EMA-EUnetHTA Bilateral Meeting Minutes – Dec 2020 Further details on collaboration with the EMA, together with past meeting minutes, can be found here.
2021 EUnetHTA Forum Welcome Guide
The 2021 EUnetHTA Forum Welcome Guide is now available. The guide forms a comprehensive overview of EUnetHTA activities as we near completion of Joint Action 3, and is recommended reading prior to the Forum on 15 April. Follow the link, or check the ‘Get Involved’ dropdown menu on our homepage and then to ‘Events’, you’ll […]
2021 EUnetHTA Forum – Agenda
The 2021 EUnetHTA Forum takes place online on 15th April. In advance of this, please follow the link to access the agenda for the day’s events and speakers. 2021 EUnetHTA Forum Agenda Also, if you were unable to register and still wish to do so, please contact us directly at eunethta@zinl.nl See you there! EUnetHTA […]
Patient group input requested for new Rapid Reviews on medicinal products for COVID-19.
EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]
EUnetHTA Magazine – Winter 2021 – now available
We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA in Europe, EUnetHTA tasks and output, and, of course, COVID-19 and the network’s reprioritization this year towards it. We normally try to publish quarterly. However, 2020 has proven to be […]
EUnetHTA – Open Letter of Comment
This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA – Open Letter of Comment For any questions regarding this, please contact the EUnetHTA Secretariat team at eunethta@zinl.nl
